Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Dow
Mallinckrodt
Johnson and Johnson
Harvard Business School

Last Updated: October 2, 2022

CLINICAL TRIALS PROFILE FOR ARAMCHOL


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Clinical Trials for Aramchol

Trial ID Title Status Sponsor Phase Summary
NCT00776841 ↗ A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers Completed Galmed Medical Reserch Phase 1 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1. To assess and characterize the safety and tolerability of Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B) 2. To assess the pharmacokinetics of Aramchol at the administered doses
NCT01094158 ↗ Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Beilinson Hospital, Petach Tikva,Israel Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
NCT01094158 ↗ Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Hadassah Medical Organization Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
NCT01094158 ↗ Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Hillel Yaffe Medical Center Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
NCT01094158 ↗ Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Holy Family Hospital, Nazareth, Israel Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
NCT01094158 ↗ Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis Completed Kaplan Hospital ,Rehovot,Israel Phase 2 Primary purpose: Compare the changes in liver triglycerides concentration in the Aramchol versus the placebo arm following three month treatment. Secondary purpose: Comparing liver enzymes, markers of endothelial dysfunction, insulin resistance, SCD1 activity and cholesterol synthesis and lipid levels, between the Aramchol and the placebo arms.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Aramchol

Condition Name

Condition Name for
Intervention Trials
Healthy 3
Healthy Volunteers 2
Liver Fibroses 1
Metabolic Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Non-alcoholic Fatty Liver Disease 4
Liver Diseases 4
Fatty Liver 4
Malnutrition 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Aramchol

Trials by Country

Trials by Country for
Location Trials
United States 11
Israel 4
Mexico 2
United Kingdom 2
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for
Location Trials
California 3
Florida 2
Texas 2
Virginia 1
North Carolina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Aramchol

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 1
Phase 2 4
Phase 1 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 8
Terminated 1
Enrolling by invitation 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Aramchol

Sponsor Name

Sponsor Name for
Sponsor Trials
Galmed Pharmaceuticals Ltd 6
Diamond Pharma Services Regulatory Affairs Consultancy 4
Analyst Research Laboratories 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Other 40
Industry 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Harvard Business School
Baxter
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.